A Study of LY3985863 in Healthy Participants

Launched by ELI LILLY AND COMPANY · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to see how a new drug called LY3985863 is tolerated by healthy Chinese adults and to learn about any side effects it might cause. The medication will be given as an injection just under the skin. During the study, participants will have blood tests to help researchers understand how the drug moves through and affects the body.

To take part, participants need to be healthy native Chinese adults within a certain weight and body mass index range, with stable weight for at least three months. People with allergies to the drug, certain health conditions, heart test abnormalities, or those currently using weight loss medications won’t be eligible. This study is not yet open for enrollment, and it aims to gather important safety information before testing the drug in patients with specific health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are native Chinese participants
• • Are overtly healthy
• • Have body weight of at least 50.0 kilogram (kg) for male or 45.0 kg for female and a body mass index of 20.0 to 30.0 kilogram per square meter (kg/m²), inclusive
• • Have a stable body weight within 3 months
• Exclusion Criteria:
• • Have known allergies to any components of the LY3985863 formulation
• • Have concomitant disease known to influence skeletal muscle protein
• • Have current or a history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication or completing study procedures, or of interfering with the interpretation of the data
• • Have a 12-lead echocardiogram (ECG) abnormality
• • Have used within 3 months or intend to use medications during the study that promote weight loss